Finasteride
medicationA prescription pill that slows male-pattern hair loss by lowering DHT.
Estradiol is a hormone that is FDA-approved, prescription only.
Also known as Estrace, Divigel, Estring, Vivelle-Dot, Climara
Estradiol is the body's main estrogen before menopause. As a prescription, it is the most effective treatment for hot flashes and night sweats, treats vaginal dryness and painful sex, and helps prevent bone loss. Women with a uterus usually also need a progestogen to protect the uterine lining.

Approved by the FDA. A licensed clinician has to decide it is right for you and prescribe it. FDA-approved, prescription only, with many generics. In November 2025 FDA moved to remove the boxed warnings on heart disease, breast cancer and dementia from hormone therapy labels, keeping the endometrial cancer warning for estrogen alone; labels are being updated in stages through 2026.
As of October 7, 2026.
Key takeaways
Falling estradiol at menopause disrupts the brain's temperature control, which causes hot flashes and night sweats, and thins the tissues of the vagina and urinary tract. Replacing estradiol eases both and slows bone loss.
Pills, patches, gels and sprays reach the whole body (systemic therapy). Low-strength vaginal rings, inserts and creams act mainly on local tissues; the Estring label says some estradiol is absorbed but exposure is generally lower than with systemic forms.



On November 10, 2025, FDA said it would remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy, keep the boxed warning for endometrial cancer on systemic estrogen-alone products, and advise starting systemic therapy before 60 or within 10 years of menopause. FDA (Nov 10, 2025): HHS removes boxed warnings from hormone replacement therapy
FDA says cardiovascular and breast cancer risks stay in the Warnings and Precautions section of the labels. FDA Consumer Update: Hormone replacement therapies can help women with bothersome menopausal symptoms (2026)
On February 12, 2026, FDA approved the first labeling changes, covering systemic estrogen-alone, estrogen plus progestogen, progestogen-alone and vaginal estrogen products. Updates for other products are still rolling out, so some generic labels still show the older box. FDA (Feb 12, 2026): FDA approves labeling changes for menopausal hormone therapy products
FDA-approved estradiol is already chemically identical to the body's own hormone. The National Academies found insufficient evidence for the clinical usefulness of compounded bioidentical hormone therapy and recommended limiting it to people who cannot use an approved product, warning about too much or too little hormone and contamination. National Academies (2020): Restrict non-FDA-approved compounded bioidentical hormones
Randomized trials and The Menopause Society's 2022 position statement rate hormone therapy the most effective treatment for hot flashes and genitourinary symptoms of menopause.
What trials and prescribing information measured over time. Everyone responds differently.
In the Divigel trials, hot flash frequency and severity fell significantly compared with placebo by week 4 at two of the strengths tested.
By week 12 all strengths in those trials had reduced hot flashes more than placebo.
The Menopause Society advises reviewing the decision regularly, as benefits and risks change with age and duration.
Menopause specialists see estradiol as the most effective treatment for moderate to severe hot flashes, with the decision shaped by age, time since menopause, route and personal risk.
The Menopause Society's 2022 position statement says hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause, and that for women under 60 or within 10 years of menopause without contraindications, the benefit-risk ratio is favorable.
The 2022 hormone therapy position statement of The North American Menopause SocietyThe same statement recommends low-dose vaginal estrogen or other therapies for genitourinary symptoms when systemic therapy is not needed, and says risks differ by type, route, timing and whether a progestogen is used.
The 2022 hormone therapy position statement of The North American Menopause SocietyIn November 2025 FDA cited randomized studies showing lower all-cause mortality and fewer fractures in women who started hormone therapy within that window.
FDA (Nov 10, 2025): HHS removes boxed warnings from hormone replacement therapyThe estradiol tablet label lists stroke, blood clots, endometrial and breast cancer, dementia in women 65 and older, and gallbladder disease among its warnings.
DailyMed: Estradiol tablets (Teva) prescribing informationSummaries of published guidelines, drug labels, regulators and reviews, each attributed to its source. DiscoverMedica does not employ clinicians.
Only a licensed clinician who knows your history can decide whether it is right for you.
These save with the compound when you add it to My Journal, so they’re on the printout for your visit.

Fill in an online intake about your symptoms, periods, personal and family history, and blood pressure.
A clinician, often one with menopause training, reviews it by message or video and recommends a form and a progestogen if you have a uterus.
The prescription is sent to a pharmacy or shipped. Generic estradiol is usually covered by insurance.
Follow-ups review symptom relief, bleeding and side effects, and whether to continue.
From each provider’s own site, checked October 7, 2026. Programs change, so confirm the details before you sign up.
15 providers list Estradiol on DiscoverMedica, lowest listed price first.
† Prices as listed by the provider when we checked; they change.
Listed prices run from $24 to $65 a month across 6 providers, as checked October 7, 2026.
Prices as listed by the provider when we checked; they change. Membership or consult fees may be separate; see each provider.
Common side effects on estradiol labels include breast tenderness, irregular bleeding or spotting, headache, bloating, nausea and, with vaginal forms, discharge or yeast infections. Serious risks listed in the warnings include blood clots, stroke and, for women with a uterus who take estrogen alone, endometrial cancer. Report new bleeding after menopause, leg swelling, chest pain or sudden headaches promptly.
Yes. Estradiol pills, patches, gels, sprays and vaginal products are FDA-approved, prescription-only treatments for menopausal hot flashes and vaginal atrophy, and some are approved to prevent osteoporosis. In 2025 and 2026 FDA began removing boxed warnings about heart disease, breast cancer and dementia from these labels, while keeping the endometrial cancer warning for estrogen alone.
Weight is not an approved use. Bloating and fluid retention are listed side effects and can make the scale move, but estradiol is not a weight-loss or weight-gain drug. Midlife weight change has many causes, so if it worries you, raise it separately with your clinician rather than expecting hormone therapy to solve it.
There is no single cut-off. The Menopause Society says the benefit-risk balance is most favorable when therapy starts before 60 or within 10 years of menopause, and that risks depend on type, route, duration and age. Many women review the decision with their clinician every year rather than stopping at a fixed date.
Vaginal estradiol acts mainly on local tissue. The Estring label says some is absorbed into the body, but exposure is generally lower than with systemic estrogens. The Menopause Society recommends low-dose vaginal estrogen for genitourinary symptoms when systemic therapy is not needed. People with a history of breast cancer should decide together with their oncologist.
Generic estradiol tablets, patches, gels and vaginal products are made by many companies, so most insurance plans cover at least one form and cash prices for generic pills are often low. Brand-name patches, gels and rings can cost more. Ask your plan which forms are on its formulary before choosing.
This is not a complete list of risks. Read the full prescribing information and any Medication Guide, and talk to a licensed clinician or pharmacist about your own situation. If you have a severe reaction, call 911. You can report side effects to the FDA through MedWatch at 1-800-FDA-1088.
Guide reviewed October 7, 2026.
Educational information only, not medical advice. It does not replace a conversation with a licensed clinician.
A prescription pill that slows male-pattern hair loss by lowering DHT.
Prescription testosterone replacement for men with confirmed low testosterone.
A pill that can raise a man's own testosterone while preserving fertility. Compounded, not approved.
A reproductive-hormone peptide studied in fertility research. Restricted from compounding.